Technetium-99m-labeled genistein as a potential radical scavenging agent

Abstract

The purpose of this study was to determine the optimum conditions for labeling genistein compounds with technetium-99m ( 99m Tc) radionuclides and the percentage of purity obtained in accordance with the requirements of the United State Pharmacopeia. The method used is optimization of several parameters including pH, SnCl 2 .2H 2 O as reducing agents, genistein concentration, and incubation time. The results showed that the optimum conditions for labeling 99m Tc-Genistein were obtained under conditions of pH 8, the amount of SnCl 2 .2H 2 O reducing agents was 30 μg, 0.5 mg genistein, and in 10 min. The optimization of this condition resulted in radiochemical purity in the labeling of 99m Tc-Genistein compounds at 95.43% ± 0.85%. The radiochemical purity of the labeling of 99m Tc-Genistein compounds has met the requirements of the United State Pharmacopeia as a compound marked for diagnosis of more than 90%.

Iodine-131 labeled genistein as a potential radiotracer for breast cancer

“…These results are also in line with the results of optimizing the labeling of genistein compounds with technetium-99m radioisotope with pH 8 as the optimum pH with purity reaching 91.97% ± 1.43% [ 18 ]. Optimization results at pH 8 indicate that this pH approaches physiological conditions, where the mechanism of action of genistein as an estrogen receptor antagonist will be stable, and can perform its function as an estrogen receptor antagonist beta sub unit [ 19 ].…”

99mTc labeled genistein kits: development methods and quality control for breast cancer radiotracer applications

“…In addition, sodium pertechnetate solution [ 99m Tc] with an activity 7.4 -17 MBq was added in the process of forming 99m Tc genistein. The radiochemical purity (RCP) of the complex formation is monitored by TLC and must ful ll the USP requirement of > 90% [14][15] .…”

Applying Quality by Design Principles in the Development and Preparation of a New Radiopharmaceutical: Technetium-99m-Imatinib Mesylate

“…Several studies concerning the usage of reducing agents such as stannous derivatives were identified in the literature. ,− …”

“…Incubation time was also determined as a critical parameter in the preparation process of radiopharmaceuticals. Studies have demonstrated that adequate labeling needs a certain amount of time. , …”

“…Studies have demonstrated that adequate labeling needs a certain amount of time. 39,44 Defining the Critical Ranges for the Identified Radiolabeling Process Variables. Radiolabeling Studies.…”